Italian pharmaceutical company Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for approximately $4.1 billion USD ($3.5 billion EUR). The deal strengthens Angelini Pharma's global presence in brain health and rare diseases while expanding into the U.S. market. Blackstone will invest €1 billion in preferred equity, and CDP Equity will acquire a 23.5% stake in Angelini Pharma for approximately €1 billion.

Private credit investments are expected to become available in 401(k) plans, opening a massive $14 trillion market opportunity. While private credit offers higher returns, it carries significant risks including illiquidity and interest rate sensitivity. Alternative asset managers like Blackstone, Apollo Global Management, and KKR are well-positioned to capitalize on this expansion without investors needing to directly buy private credit funds.

GNI Group Ltd. has completed its acquisition of Ayumi Pharmaceutical Holdings Co., Ltd. from Blackstone and other shareholders for approximately JPY 44.8 billion. The acquisition marks GNI Group's entry into Japan's pharmaceutical market, establishing what the company calls its 'Second Founding Phase' as a global biopharma company. Ayumi Pharmaceutical, with JPY 38.5 billion in annual revenue and over 80% market share in acetaminophen products, will operate as a wholly owned subsidiary while maintaining its brand names and product portfolio.

Digital Realty announced the pricing of an underwritten public offering of 12.3 million shares by Blackstone affiliates at $185 per share. The offering is contingent on Digital Realty's acquisition of Blackstone's interests in two Northern Virginia data center joint ventures (Digital Carver Dulles 9 and Digital Carver Brickyard), expected to close on June 30, 2026. Digital Realty will not receive proceeds from the secondary offering.

Blackstone and other major private credit funds are limiting investor redemptions as concerns grow about credit quality and economic conditions. Blackstone capped redemptions at 5% despite receiving 10% requests. While redemption limits help stabilize markets by preventing forced asset sales, they also signal underlying concerns about loan performance and may fuel investor anxiety.

Oracle's recent stock sell-off is viewed as an overreaction to SaaS disruption and debt concerns, despite the company's strong position as a blue-chip AI infrastructure player with a trillion-dollar backlog. Trading at only 22X current-year earnings with potential P/E ratios falling to 8X within four years, analysts see significant upside potential of 50-500% as backlog converts to revenue. The stock is expected to rebound near-term with catalysts including Q1 2027 earnings in September and Oracle's AI World conference in October.

GPUs have evolved from gaming chips into a distinct financial asset class, with standardized pricing, financing structures, and risk-transfer tools emerging. The GPU financing market reached $20-34 billion by early 2026, driven by massive AI infrastructure spending. However, the asset class faces challenges including uncertain depreciation rates, volatile rental prices, ecosystem concentration, and risks from custom silicon and export controls.

Broadcom stock fell 3.17% on Tuesday as investors rotated away from growth-oriented technology stocks amid a broader market sell-off. The decline was triggered by Broadcom's unchanged AI revenue outlook for fiscal 2027 despite strong Q2 results, disappointing investors seeking accelerated growth signals. The broader Nasdaq declined 2.06% as market sentiment shifted toward defensive sectors like real estate and healthcare.

GNI Group announced its acquisition of Ayumi Pharmaceutical Holdings for approximately ¥44.8 billion from shareholders led by Blackstone. The transaction establishes a large-scale pharmaceutical platform in Japan, with combined fiscal 2026 revenue expected to reach ¥65.2 billion. Ayumi Pharmaceutical, a specialty pharmaceutical company with leading positions in pain management and rheumatology, will become a wholly owned subsidiary of GNI Group.

GNI Group announced the acquisition of Ayumi Pharmaceutical Holdings for approximately ¥44.8 billion, making it a wholly owned subsidiary. The transaction establishes a large-scale pharmaceutical platform in Japan with leading positions in pain management and rheumatology, expected to increase combined fiscal 2026 revenue to approximately ¥65.2 billion. The acquisition strengthens GNI Group's commercial capabilities and geographic diversification across Japan, China, and the United States.

Alterra IOS closed a $244 million loan from Blackstone Real Estate Debt Strategies to support its industrial outdoor storage platform expansion. The financing, secured by 37 properties across 27 markets, brings Alterra's total institutional debt to over $1.8 billion. This marks Blackstone's sixth IOS sector loan, with total exposure exceeding $1.1 billion. Alterra has acquired over 470 properties across 39 states using an innovative equity pledge framework instead of traditional mortgage structures.

Hedge fund billionaire Daniel Loeb's Third Point LLC added significant positions in Meta Platforms and Alphabet in Q1 FY26, acquiring 90,000 and 175,000 shares respectively. Meta beat earnings expectations with $56.31B revenue and announced increased infrastructure spending, while Alphabet reported strong quarterly earnings of $5.11 per share and plans to raise $80B for AI infrastructure investments. Both companies are aggressively expanding AI capabilities through partnerships, acquisitions, and new product launches.